ABSTRACT
Objectives Evaluate neurocognitive health and its response to interventions in older, obese patients with heart failure with preserved ejection fraction (HFpEF).
Background Neurocognitive dysfunction may be an underrecognized feature of HFpEF that responds to weight-loss interventions.
Methods We first compared detailed baseline cognitive testing (Uniform Data Set version 3 and Rey Auditory Verbal Learning Test [RAVLT]), and brain volumes and cerebral blood flow (CBF) from 3T magnetic resonance imaging between older patients with HFpEF (n=46) and healthy age-matched controls (HC; n=22). The HFpEF patients were then randomized to a 20-week caloric restriction (CR) intervention with either aerobic-only (CR+AT; n=23) or aerobic+resistance exercise training (CR+AT+RT; n=23), and repeated cognitive testing and neuroimaging post-intervention. Cognitive scores were normalized to national data and transformed to z-scores for global, memory, attention, executive function, visuospatial, and language fluency domains.
Results Compared to HC, participants with HFpEF had significantly lower baseline global cognitive performance, and lower global, visuospatial processing and language fluency domain z-scores than normative means. Following the diet and exercise intervention, there were significant improvements in global (+0.6 [95% CI: 0.3, 0.8]) and category fluency (+0.2 [95% CI: −0.004, 0.3]) z-scores, and in RAVLT immediate (+0.6 [95% CI: 0.1, 1.0] points) and delayed (0.9 [95% CI: 0.2, 1.6] points) recall. Only CR+AT+RT was associated with improved phonemic fluency z-score (+0.4 [95% CI: 0.1, 0.7]). There were no significant intervention effects on brain volumes or CBF.
Conclusions Older, obese patients with chronic HFpEF have significant cognitive deficits that are ameliorated by diet and exercise interventions.
Competing Interest Statement
Dr. Kitzman has received honoraria as a consultant outside the present study for Bayer, Pfizer, Corvia Medical, Boehringer Ingelheim, Ketyo, Rivus, NovoNordisk, AstraZeneca, and Novartis; grant funding from Novartis, Bayer, Pfizer, NovoNordisk, and AstraZeneca; and has stock ownership in Gilead Sciences.
Clinical Trial
NCT02636439
Funding Statement
This work was supported by National Institute on Aging (Bethesda, MD) grants K01AG073581 to CLS; R01AG018915-16S1 and K01AG043547 to CEH; R01AG018915, R01AG045551, P30AG021332, U24AG059624, and U01AG076928 to DWK; R21AG051077 to AJAM; National Heart, Lung, and Blood Institute (Bethesda, MD) grant U01HL160272 to DWK; American Heart Association (Dallas, TX) grant 15MCPRP25680019 to AJAM; and in part by the Kermit G. Phillips II Endowed Chair in Cardiovascular Medicine (Wake Forest University School of Medicine) to DWK. No sponsor had any role in the design or conduct of this study; in the collection, analysis, or interpretation of data; nor in the preparation, review, or approval of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The SECRET-II trial was approved by the Wake Forest University School of Medicine Institutional Review Board and completed in accordance with the Declaration of Helsinki. All participants provided written informed consent prior to enrollment.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request from researchers trained in the responsible conduct of research in human subjects.
NON-STANDARD ABBREVIATIONS
- AT
- aerobic exercise training
- BMI
- body mass index
- CBF
- cerebral blood flow
- CI
- confidence interval
- CR
- caloric restriction
- FLAIR
- fluid-attenuated inversion recovery
- HF
- heart failure
- HFpEF
- heart failure with preserved ejection fraction
- HFrEF
- heart failure with reduced ejection fraction
- ICV
- intracranial volume
- MRI
- magnetic resonance imaging
- MoCA
- Montreal Cognitive Assessment
- pcASL
- pseudocontinuous arterial spin labeling
- RAVLT
- Rey Auditory Verbal Learning Test
- RT
- resistance exercise training
- SECRET-II
- Study of the Effect of Caloric Restriction and Exercise Training in Patients with Heart Failure and a Normal Ejection Fraction
- UDSv3
- Uniform Data Set version 3
- WMH
- white matter hyperintensity
